CoChat
Cited by 201

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study

Open access
Ormiston, John A., Serruys, Patrick W., Onuma, Yoshinobu, van Geuns, Robert-Jan, de Bruyne, Bernard, Dudek, Dariusz, Thuesen, Leif, Smits, Pieter C., Chevalier, Bernard, McClean, Dougal, Koolen, Jacques, Windecker, Stephan, Whitbourn, Robert, Meredith, Ian, Dorange, Cecile, Veldhof, Susan, Hebert, Karine Miquel, Rapoza, Richard, Garcia-Garcia, Hector M. · 2012 · Circulation: Cardiovascular Interventions

Abstract

Background—: Nonserial observations have shown this bioresorbable scaffold to have no signs of area reduction at 6 months and recovery of vasomotion at 1 year. Serial observations at 6 months and 2 years have to confirm the absence of late restenosis or unfavorable imaging outcomes. Methods and Results—: The ABSORB trial is a multicenter single-arm trial assessing the safety and performance of an everolimus-eluting bioresorbable vascular scaffold. Forty-five patients underwent serial invasive imaging, such as quantitative coronary angiography, intravascular ultrasound, and optical coherence tomography at 6 and 24 months of follow-up. From 6 to 24 months, late luminal loss increased from 0.16±0.18 to 0.27±0.20 mm on quantitative coronary angiography, with an increase in neointima of 0.68±0.43 mm 2 on optical coherence tomography and 0.17±0.26 mm 2 on intravascular ultrasound. Struts still recognizable on optical coherence tomography at 2 years showed 99% of neointimal coverage with optical and ultrasonic signs of bioresorption accompanied by increase in mean scaffold area compared with baseline (0.54±1.09 mm 2 on intravascular ultrasound, P =0.003 and 0.77±1.33 m 2 on optical coherence tomography, P =0.016). Two-year major adverse cardiac event rate was 6.8% without any scaffold thrombosis. Conclusions—: This serial analysis of the second generation of the everolimus-eluting bioresorbable vascular scaffold confirmed, at medium term, the safety and efficacy of the new device. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00856856.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circinterventions.112.971549

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 201

Metadata

Authors
Ormiston, J. A., Serruys, P. W., Onuma, Y., van Geuns, R.-J., de Bruyne, B., Dudek, D., Thuesen, L., Smits, P. C., Chevalier, B., McClean, D., Koolen, J., Windecker, S., Whitbourn, R., Meredith, I., Dorange, C., Veldhof, S., Hebert, K. M., Rapoza, R., & Garcia-Garcia, H. M.
Venue
Circulation: Cardiovascular Interventions
Published
2012-10
Volume
5
Issue
5
Pages
620-632
ISSN
  • 1941-7632 (ISSN-L)
  • 1941-7640
OpenAlex
W2548646455
Cited by
201
References
1
FWCI
30.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study. https://app.cochat.ai/papers/10.1161/circinterventions.112.971549
The paper
Ormiston, J. A., Serruys, P. W., Onuma, Y., van Geuns, R.-J., de Bruyne, B., Dudek, D., Thuesen, L., Smits, P. C., Chevalier, B., McClean, D., Koolen, J., Windecker, S., Whitbourn, R., Meredith, I., Dorange, C., Veldhof, S., Hebert, K. M., Rapoza, R., & Garcia-Garcia, H. M. (2012). First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold: A Multi-Imaging Modality Study. Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.112.971549

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.